Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Follow-up visits for low-dose ketamine treatment typically happen two to three times per week during the first two to four weeks, then space out to every two to four weeks once your dose and response stabilize. How often you're seen depends heavily on which product you're using: esketamine (Spravato), a nasal spray that is the only ketamine-based treatment with FDA approval for treatment-resistant depression, follows a fixed monitoring schedule set by its Risk Evaluation and Mitigation Strategy (REMS) program. Off-label low-dose ketamine, given by IV, intramuscular injection, oral tablet, or sublingual troche, has no regulatory visit requirement, so the interval is set by your prescriber based on published protocols and your individual response.
This is educational information, not medical advice. Only a licensed prescriber who has evaluated your history, response, and side effects can set the right follow-up interval for you.
Quick Answer
Most low-dose ketamine protocols schedule two to three monitored sessions per week for two to four weeks (the induction phase), then follow-up every two to four weeks once a maintenance dose is established. Esketamine (Spravato) follows an FDA-mandated REMS schedule: twice-weekly visits for the first month, tapering to weekly or every-other-week sessions afterward. Off-label ketamine follow-up intervals are set by your prescriber, not a regulatory body, and can shift based on your response, side effects, and route of administration. Ask your prescriber to state your specific schedule in writing so you know what to expect.
Why Visits Cluster at the Start
A 2017 consensus statement on ketamine for mood disorders, published in JAMA Psychiatry by Sanacora and colleagues, recommends an initial series of closely spaced sessions, commonly around six infusions over two to three weeks, with clinical reassessment before any maintenance plan begins. That front-loaded schedule exists because early response and side-effect patterns (blood pressure changes, dissociation, nausea) are the most useful signal for whether low-dose ketamine is worth continuing and at what ketamine depression dose.
The FDA's approval of esketamine formalized a similar front-loaded structure into a regulatory requirement. According to the FDA's 2019 approval announcement, Spravato is dispensed only through a certified REMS program that requires patients to be monitored on-site for at least two hours after each dose, with more frequent visits during the induction phase and a gradual shift to less frequent maintenance visits as treatment continues.
Typical Follow-Up Timeline
Induction (weeks 1-4)
Two to three monitored sessions per week to establish an effective, tolerable dose within the sub-anesthetic range and catch early side effects.
Consolidation (weeks 4-8)
Visits taper to once weekly as your prescriber confirms the dose is holding and checks for tolerance or diminishing response.
Maintenance (ongoing)
Follow-up every two to four weeks for as long as treatment continues, with periodic reassessment of whether the dose, frequency, or the treatment itself still makes sense.
Taper or discontinuation review
A dedicated visit to reassess symptom stability and, if appropriate, plan a gradual reduction rather than an abrupt stop.
What Happens at a Follow-Up Visit
A follow-up visit is more than a check-in. It typically includes a blood pressure and heart rate check (ketamine can transiently raise both), a structured mood scale such as the PHQ-9 for depression, a review of dissociative or psychotomimetic side effects, and, for patients on longer-term IV or intramuscular protocols, screening for urinary or bladder symptoms linked to chronic ketamine exposure. Your prescriber will also review whether your low dose ketamine regimen still fits your weight, kidney and liver function, and any new medications, since these factors can shift how much drug reaches effective concentrations and how long it stays active.
If you're on a self-tracking routine between visits, bringing that data in gives your prescriber more to work with than a memory of "some good days and some bad days." Structured tracking between appointments, as described in our guide on how to track symptoms between ketamine treatments, makes it easier to spot a real trend versus normal day-to-day variation.
Compare low-dose options
Review routes, dosing discussions, and alternatives before speaking with a clinician.
Compare optionsBefore Your Next Follow-Up
- Bring a symptom log covering the days since your last dose, not just today
- Note any new medications, supplements, or alcohol use since the last visit
- Write down side effects even if they seemed minor, including urinary changes or mood swings
- Ask whether your current interval still matches your response, or whether it should be lengthened or shortened
- Confirm who to call if a problem comes up before your next scheduled visit
Don't stretch intervals on your own
Skipping or self-extending follow-up visits removes the checkpoints that catch rising blood pressure, bladder symptoms from cumulative exposure, or a fading response before it becomes a bigger problem. If a scheduled visit isn't working for you, the fix is asking your prescriber to adjust the interval, not skipping it.
What Changes the Schedule
Route of administration matters: IV and intramuscular protocols usually require more in-clinic visits because they're delivered on-site, while oral and sublingual options, such as those covered in our ketamine troche dosage guide, may allow longer gaps between in-person checks with more reliance on telehealth or patient-reported outcomes. Indication matters too: chronic pain protocols and depression protocols draw on different, and generally thinner, evidence bases, and prescribers may space visits differently depending on which one you're being treated for. Age and organ function also shift the plan; older adults and patients with reduced kidney or liver clearance often need closer spacing, a point covered in our overview of renal and hepatic dose adjustments. None of these adjustments should happen without your prescriber's input, and there's no single published standard that fits every patient, since the evidence behind off-label low-dose ketamine protocols still comes mainly from small trials and clinical case series rather than large, definitive studies.
Keep Reading Dosing Guides
See how dose, route, and follow-up frequency fit together across low-dose ketamine protocols.
Frequently Asked Questions
Some follow-up visits, especially symptom and side-effect check-ins for oral or sublingual protocols, can happen by telehealth. Esketamine (Spravato) visits cannot, since the FDA's REMS program requires in-person, on-site monitoring for at least two hours after each dose. Ask your prescriber which of your visits require in-person monitoring.
Missing a follow-up can delay dose adjustments and side-effect monitoring, and some clinics require a make-up visit before administering another dose. Call your prescriber's office as soon as you know you'll miss an appointment rather than waiting until your next scheduled dose.
There's no fixed endpoint published in the evidence base. Many maintenance protocols continue with visits every two to four weeks for as long as the treatment shows benefit, with periodic reassessment, often every few months, of whether to continue, adjust, or begin a taper.
Not every visit. Baseline labs (kidney and liver function, sometimes cardiac screening) are common before starting treatment, with periodic rechecks at intervals your prescriber sets rather than at every single follow-up.
Share
Related Reading
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.